Argenx SE, a biotechnology company focused on antibody-based therapies for severe autoimmune diseases and cancer, has demonstrated market leadership with a notable increase in its Relative Strength Rating.

This technical performance improvement indicates a strong upward trend in the company’s stock price. Key metrics contributing to this trend include:

• A recent Relative Strength Rating of 95, indicating a strong upward trend
• A stock price above its 52-week low, suggesting a positive outlook

However, the recent FDA approval of Johnson & Johnson’s IMAAVY, a treatment for generalized myasthenia gravis, may pose a challenge to Argenx’s market position. IMAAVY will compete with Argenx’s VYVGART in the myasthenia gravis market, potentially impacting Argenx’s market share.

Notably, Argenx’s stock price has remained relatively stable, with a recent close price above its 52-week low. This stability suggests that investors remain confident in the company’s prospects, despite potential competition from IMAAVY.